Thermo Fisher Scientific opened a 53,000‑square‑foot Advanced Therapies Collaboration Center (ATxCC) in Philadelphia on November 18, 2025. The new facility, located within BioLabs for Advanced Therapeutics, offers integrated laboratory space, expert scientists, and advanced process‑development technologies to biotech and biopharma companies working on cell and gene therapies (CGT). The center is designed to help customers move from early research to clinical readiness, addressing the “valley of death” that often stalls CGT development.
The opening comes on the heels of a strong Q3 2025 earnings report in which Thermo Fisher generated $11.12 billion in revenue, up 5 % year‑over‑year, and reported adjusted earnings per share of $5.79, beating analyst expectations by $0.29. Adjusted operating margin expanded to 23.3 %, reflecting disciplined cost management and a favorable product mix. The company’s robust financial performance provides the capital base and confidence needed to invest in high‑growth areas such as CGT.
The global CGT market is projected to grow from $20.5 billion today to $128.8 billion by 2035, underscoring the strategic importance of Thermo Fisher’s new center. By embedding the ATxCC within a biotech‑focused ecosystem, Thermo Fisher is positioning itself as a collaborative partner rather than a traditional vendor, aiming to capture a larger share of the expanding CGT pipeline and to deepen relationships with early‑stage developers.
Nicole Brockway, president of Thermo Fisher’s biosciences division, said the Philadelphia center “is designed to help innovators overcome critical hurdles in developing cell and gene therapies. It will play a key role in supporting customers as they progress from the lab to the clinic and, most importantly, bring transformative therapies to patients faster.” CEO Marc N. Casper added that the company’s “proven growth strategy and PPI Business System” have delivered “excellent operational performance” and that the firm’s “trusted partner status” is resonating strongly with customers.
The new collaboration center reinforces Thermo Fisher’s commitment to the CGT space and signals a broader shift toward integrated, value‑added services for life‑science companies. With a strong financial foundation and a clear strategic focus on high‑growth therapeutic modalities, Thermo Fisher is well positioned to support the next generation of cell and gene therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.